Miniatura

Fitxers

701096.pdf (1.67 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2020-05-13

Llicència de publicació

cc-by (c) Lahiguera, Álvaro et al., 2020
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/163068

Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.15252/emmm.201911217

Resum

Mitochondrial metabolism and the generation of reactive oxygen species (ROS) contribute to the acquisition of DNA mutations and genomic instability in cancer. How genomic instability influences the metabolic capacity of cancer cells is nevertheless poorly understood. Here, we show that homologous recombination-defective (HRD) cancers rely on oxidative metabolism to supply NAD+ and ATP for poly(ADP-ribose) polymerase (PARP)-dependent DNA repair mechanisms. Studies in breast and ovarian cancer HRD models depict a metabolic shift that includes enhanced expression of the oxidative phosphorylation (OXPHOS) pathway and its key components and a decline in the glycolytic Warburg phenotype. Hence, HRD cells are more sensitive to metformin and NAD+ concentration changes. On the other hand, shifting from an OXPHOS to a highly glycolytic metabolism interferes with the sensitivity to PARP inhibitors (PARPi) in these HRD cells. This feature is associated with a weak response to PARP inhibition in patient-derived xenografts, emerging as a new mechanism to determine PARPi sensitivity. This study shows a mechanistic link between two major cancer hallmarks, which in turn suggests novel possibilities for specifically treating HRD cancers with OXPHOS inhibitors.

Matèries

Tumors, Metabolisme, Oxidació, Inhibidors enzimàtics

Matèries (anglès)

Tumors, Metabolism, Oxidation, Enzyme inhibitors

Citació

Col·leccions

Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Ciències Fisiològiques)
Articles publicats en revistes (Infermeria Fonamental i Clínica)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

LAHIGUERA, Álvaro, HYROSSOVÁ, Petra, FIGUERAS I AMAT, Agnès, GARZÓN, Diana, MORENO, Roger, SOTO CERRATO, Vanessa, MCNEISH, Iain, SERRA ELIZALDE, Violeta, LÁZARO GARCÍA, Conxi, BARRETINA, Pilar, BRUNET, Joan, MENÉNDEZ, Javier a., MATIAS-GUIU, Xavier, VIDAL-BEL, August, VILLANUEVA GARATACHEA, Alberto, TAYLOR-HARDING, Barbie, TANAKA, Hisashi, ORSULIC, Sandra, JUNZA MARTÍNEZ, Alexandra, YANES, Oscar, MUÑOZ PINEDO, Cristina, PALOMERO, Luis, PUJANA GENESTAR, M. ángel, PERALES LOSA, Carlos, VIÑALS CANALS, Francesc. Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors. _EMBO Molecular Medicine_. 2020. Vol. e11217. [consulta: 22 de gener de 2026]. ISSN: 1757-4676. [Disponible a: https://hdl.handle.net/2445/163068]

Exportar metadades

JSON - METS

Compartir registre